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EFFECTS of the drugs FK 506 and CyA on lympho-
cyte function have been mostly studied in vitro and 
in vivo in animal models. 1-5 Little information is available 
about changes in the immune system of patients who, 
having undergone orthotopic liver transplantation (OL T), 
are treated with immunosuppressive drugs. To evaluate 
cellular immunity of patients treated for prolonged periods 
with FK 506 or CyA, serial immunologic monitoring was 
performed in liver transplant recipients. The purpose of 
this monitoring was to compare long-term effects of Cy A 
and FK 506 on immunologic function and absolute num-
bers of circulating lymphocyte subsets in liver transplant 
recipients, to determine if these drugs had similar or 
different immunosuppressive effects in vivo. 
METHODS AND RESULTS 
The patients monitored for immunologic parameters represent a 
subset of liver transplant recipients participating in the random-
ized FK 506/CyA trial conducted at the University of Pittsburgh 
Medical Center in 1990-91. A total of 96 immunologically moni-
tored patients were randomized as follows: 55 to the CyA arm, 51 
to FK 506 arm. Forty-one patients, initially randomized to CyA, 
were crossed over to FK 506. 
Immunological parameters monitored included 20 endpoints as 
follows: total T, B. and NK cells; subsets ofT, B, and NK cells; 
activated T, B, and NK cells; CD4/CD8 ratio; natural killer (NK) 
activity; Iymphokine-activated killer (LAK) cell generation; pro-
liferative responses to OKT3 MAb; in vitro production of IFN-y; 
and in vitro production of IL-2. 
Peripheral blood mononuclear cells (PBMNC) of the patients 
were collected at the multiple time points, starting with a baseline 
(day 1) specimen obtained immediately before transplantation, 
and then continuing after transplantation at regular intervals (see 
Fig I), and, additionally, at the time of major events such as viral 
infection, rejection, or a second transplant. To date, a partial data 
analysis has been completed for 96 liver transplant recipients 
monitored for up to 180 days. 
The study was performed at the Immunologic Monitoring and 
Diagnostic Laboratory (lMDL) of the Pittsburgh Cancer Institute. 
Freshly harvested PBMNC were used for two-color flow cytom-
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'" IL Fig 1. Serial immunologic mon-
itoring of a liver transplant recip-
ient. Absolute numbers of circu-
lating IL-2W T lymphocytes 
were measured by two-color flow 
cytometry. Arrows denote epi-
sodes of histologically docu-
mented rejection. V = viral infec-
tion. C = crossover from CyA to 
FK 506. FK 506 serum level was 
measured by ELISA. 
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etry, 4-hour slCr-release NK cell assays, and to generate LAK 
cells in response to 1000 Cetus U/mL of IL-2. Cells were cryo-
preserved for in vitro proliferation in response to OKT3 MAb and 
phorbol ester as well as OKT3-induced IL-2 or IFN-yproduction. 
Methods used for serial monitoring of the above parameters have 
been described by us earlier.6•7 All flow cytometry data are 
presented as absolute numbers of circulating cells. The results 
were analyzed using a statistical model, which did not adjust for 
infections or rejections experienced by the CyA-treated vs FK 
506-treated patients, but which adjusted for crossovers from CyA 
to FK 506. All major events occurring during monitoring, such as 
a crossover from CyA to FK 506; rejection episodes which were 
confirmed histologically; viral, bacterial, or fungal infections; 
development of PTLD; immunosuppression as reflected by the 
blood level of FK 506 or CyA (determined by ELISA); and the 
administration of other medications, eg, solumedrol, were docu-
mented and recorded for each patient studied. 
An example of immunologic monitoring as performed in this 
study is shown in Fig 1. Changes in the absolute number of 
circulating CD3+CD25+ (IL-2R+) T lymphocytes during a post-
transplant immunosuppressive therapy in a single patient treated 
with FK 506 are shown. Note that the serum levels of FK 506 as 
well as episodes of rejection or viral infection are shown also to 
indicate that in this, and all other patients monitored, the immu-
nologic data were interpreted with respect to these parameters. 
Initially, analyses were performed to compare long-term effects 
of the drug on various immunologic parameters in the cohort of 
patients treated with CyA vs those treated with FK 506. The 
results of this comparison showed that no significant differences 
could be detected between functions of lymphocytes obtained 
from patients treated with FK 506 or CyA. For example, NK 
activity (Fig 2) was comparable in patients treated with FK 506 vs 
CyA. Patients treated with CyA had significantly higher (P < .02) 
WBC counts than those treated with FK 506, with an estimated 
difference of >50% between CyA vs FK 506 groups (Fig 3a). 
Although no statistically significant differences were observed 
between the two patient groups in absolute numbers of lympho-
cytes, lymphocyte subsets, or activated lymphocytes, patients on 
Cy A generally had higher numbers of these cells in the blood than 
patients treated with FK 506. For example, a >50% difference in 
B cells (CD23+), with a higher number of circulating B cells in 
CyA-treated individuals, was observed (Fig 3b). As Fig 3b indi-
cates, a large spread in the data presumably accounts for a lack of 
statistical significance in the observed differences. 
In addition to comparing immune cell numbers and function in 
patients treated with FK 506 vs CyA, it was also possible to 
inquire if significant changes from baseline were observed in both 
immune function as well as absolute numbers of various lympho-
cyte subsets during long-term therapy. A series of statistical 
analyses were performed in which immunologic measurements 
over time obtained for each patient after transplantation were 
compared to his or her own baseline (ie, measurement immedi-
ately before transplantation). The data obtained for patients on 
FK 506 or CyA were combined for this analysis, so that all 96 
patients were treated as one group. The results are presented as 
"boxplots" (shown in Fig 4). 
The following changes from baseline were observed during 
long-term posttransplant immunosuppression. The absolute num-
ber of total lymphocytes was significantly increased (P < .001) 
throughout therapy. This increase involved total T lymphocytes 
(results not shown) and B lymphocytes (Fig 4b) but not NK 
(CD3-CD56+) cells (Fig 4d). In terms of lymphocyte subsets, 
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Fig 2. A comparison of NK activity in patients randomized to FK 
506 vs CyA. The solid lines are medians, and interrupted lines 
denote 5% and 95% confidence limits. No statistically significant 
difference was observed between patients treated with FK 506 and 
CyA. 
numbers of activated T cells (CD3+HLA-DR+; CD3+CD25+ in 
Fig 4a), non-MHC-restricted T cells (CD3+CD56+) and B cells 
(CD23+ as well as CD21 +) were significantly and persistently 
elevated in the circulation during therapy. The CD4/CD8 ratio was 
decreased, due mainly to a more substantial rise in numbers of 
CD8+ cells, which was consistently greater than that in CD4+ 
cells (data not shown). Although the absolute numbers ofNK cells 
did not change, their proportion in relation to T and B lympho-
cytes was decreased and, thus, not surprisingly, NK activity was 
significantly (P < .001) depressed in these patients (Fig 4c). In 
contrast, the ability of patients' PBMNC to respond to IL-2 in 
vitro by activation and generation of killing function remained 
unchanged relative to baseline (results not shown). The changes in 
numbers or function of PBMNC listed above were all highly 
significant (see Fig 4) for all time points following transplantation. 
Next, NK and LAK activities prior to (at baseline) and after 
transplantation (during immunosuppressive therapy) were com-
pared to those determined in our laboratory for a large group (n = 
120) of normal, healthy volunteers. As Fig 5a shows, NK activity 
of patients on immunosuppressive drugs, as a group, was signifi-
cantly lower than that of a normal control group. Nevertheless, 
there were many patients whose NK activity was within a normal 
range (Fig 5a). On the other hand, LAK activity in the patient 
group was comparable to that in normal volunteers, both at 
baseline and during therapy with FK 506 or CyA. In addition, 
PBMNC obtained from a small subgroup of patients (n = 12) on 
immunosuppressive therapy with FK 506 or Cy A were induced in 
vitro with OKT3 MAb (100 ng/mL)/phorbolester (PMA, 20 
ng/mL), and proliferation as well as IL-2 or IFN-y production 
DIMUNE ENDPOINT=LOG WBC 
• FK506 
o CsA 
IItud7 0." Number 
a 
LOG CD23+ (86) 
• FUII6 
o CsA 
b 
Fig 3. A comparison of absolute numbers of WBC (8), and circulating B lymphocytes (b) in patients randomized to FK 506 vs CyA. In 
(8), P < .02 for CyA vs FK 506. In (b), P < .06 for CyA vs FK 506. See legend to Fig 2 for symbol description. 
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Fig 4. Long-term effects of immunosuppressive therapy with FK 506 or CyA in all 96 liver transplant recipients. Shown are changes from 
baseline (pretransplant) during 180 days of therapy for absolute numbers of circulating CD3+CD25+ T lymphocytes (8) or CD23+ B 
lymphocytes (b), and for NK activity (c) or absolute numbers of CD3-CD56+ NK cells (d). The solid line is the median of differences from 
the baseline (interrupted line), with "boxes" indicating the 25th and 75th quartlles, and "whiskers" showing extended ranges for each 
parameter. All changes are significant at P < .001 or lower. 
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Fig 5. Functional characteristics of PBMNC obtained from patients treated with FK 506 or CyA. (8) NK and LAK activities of fresh 
PBMNC" before and during therapy are shown. The solid horizontal lines are medians, at 5% and 95% confidence limits, for 120 normal 
PBMNC" Median NK activity (in LU) was significantly (P < .01) lower for PBMNC obtained during therapy than those obtained before 
therapy. LAK activity was unchanged pre- and post-therapy. (b) In vitro responses of patient and normal PBMNC to OKT3/PMA are 
compared in terms of prOliferation and IL-2 or IFN-y production. Medians are indicated by horizontal lines. Differences between patient and 
normal cells were significant at P < .01. 
were measur~d in the supernatants of these cells. In parallel 
experiments, PBMNC obtained from normal volunteers (n = 12) 
were similarly induced in vitro. When compared to normal con-
trols, PBMNC of patients treated with immunosuppressive drugs 
had significantly decreased functions in vitro (Fig 5b). Neverthe-
less, these functions were within a lower normal range (Fig 5b). 
These results led us to conclude that lymphocytes obtained from 
patients on long-term therapy with immunosuppressive drugs, 
when washed off from the drug, retain the capability to respond in 
vitro to various specific (eg, OKT3) or nonspecific (eg, IL-2) 
signals. 
DISCUSSION 
Longitudinal immunologic monitoring of 96 patients who 
underwent OLT, and were randomized to receive FK 506 
or Cy A therapy, was performed, and the data available for 
various time points up to 180 days posttransplantation 
were used for preliminary statistical analysis. The hypoth-
esis tested in this analysis concerned a greater in vivo 
immunosuppressive potential of FK 506, which was shown 
to be 10 to 100 times more efficient than Cy A in suppress-
ing immune responses of human lymphocytes in vitro l •S 
and of the immune system in rodents in vivo. I The 
comparison of FK 506 vs CyA effects in liver transplant 
recipients indicated that lower numbers of WBC, lympho-
cytes, and activated lymphocyte subsets were present in 
the peripheral blood of patients treated with FK 506. At 
the same time, no differences were observed in functional 
properties (ie, NK activity or the ability to respond to 
IL-2) of PBMNC obtained from the blood of those two 
groups of patients at anytime in the course of monitoring. 
Also, no statistically significant differences were detected 
in the frequency of rejection or infection episodes in this 
subset of patients randomized to FK 506 or CyA. Thus, it 
appears that FK 506 may be more efficient than CyA in 
controlling the entry of activated T lymphocytes and 
CD23 + B cells into the peripheral circulation from lym-
phoid organs. FK 506 seemed not to be more effective than 
Cy A in down-regulating functions of PBMNC in the cir-
culation. 
To further define long-term effects of FK 506 and Cy A 
on immune cell numbers and function, changes relative to 
pretransplant baseline levels in these parameters were 
examined. Highly significant increases in the number of 
circulating T and B lymphocytes, but not NK cells, and 
especially, of activated lymphocyte subsets observed in 
these patients, persisted through the entire posttransplant 
period. It could be argued that such rises in activated 
T-Iymphocyte numbers, including non-MHC-restricted 
cytolytic T cells (CD3 + CD56 +), are not consistent with the 
state of drug-induced immunosuppression in patients 
treated with FK 506 or CyA. However, it is possible that 
activated T and B lymphocytes are being continuously 
released into the circulation from lymphoid organs, where 
an intense immune response to the graft is ongoing, despite 
therapy with immunosuppressive drugs. An alternative 
explanation might be that extravasation and/or migration 
of lymphocytes from the blood to lymphoid and other 
tissues is inhibited or altered by the drugs, resulting in 
LYMPHOCYTE FUNCTION WITH FK 506 AND CyA 
accumulation of these cells in the peripheral circulation. 
On the other hand, the presence of activated lymphocytes 
in the peripheral blood of these transplanted and immuno-
suppressed patients may be related to frequent viral and 
other infections, much like elevated numbers of circulating 
activated T cells in patients with AIDS and opportunistic 
infections. 9 In addition, persistently elevated numbers of 
activated B cells in the circulation of our patients might be 
a factor contributing to the development of posttransplant 
lymphoproliferative disease (PTLD), known to occur in a 
small proportion of transplanted individuals treated with 
immunosuppressive therapy. 10 
Functional evaluations of lymphocytes Qbtained from 
patients treated with FK 506 or Cy A showed that their 
ability to respond to IL-2 was normal, but NK activity and 
in vitro responses to the TCR-mediated signal (OKT3) 
were depressed relative to those of normal lymphocytes. 
Thus, despite the observed increased numbers of circulat-
ing activ~ted lymphocytes, immunologic functions ofthese 
cells appeared to be tempered by the presence of FK 506 
or Cy A in the serum. In individual patients, these func-
tions did not seem to be lower during episodes of rejection 
or elevated at the time of viral infections. However, only a 
small group of 12 patients was so far analyzed for changes 
in immune functions relative to rejection or infection 
episodes or serum drug levels. Further analysis of the data 
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is in progress to more precisely examine the relationship 
between these parameters and immune function. 
Overall, this first longitudinal study of immune cells in 
liver transplant recipients treated with either FK R~ or 
Cy A for a prolonged period of time indicated that these 
drugs appear to have profound effects on lymphocyte 
kinetics, and somewhat less pronounced but detectable 
effects on certain other, but clearly not all, lymphocyte 
functions. 
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